Cardiometabolic Health Congress

JUNE 27, 2024

Competence in selecting treatments for long-term obesity management rose from 43% pre-test to 95% post-test. Neha Agarwal, PhD, Clinical Director at Cardiometabolic Health Congress , Informa Connect, recently presented significant findings at the 84th American Diabetes Association (ADA) Scientific Sessions.

CME 59

CME Diabetes Obesity Education 59

Cardiometabolic Health Congress

OCTOBER 30, 2024

This patient’s case presents a common and challenging scenario in primary care and endocrinology, where T2D, obesity, and metabolic dysfunction intersect with liver disease. Exercise : Moderate physical activity is essential for weight management and potentially improving liver fat levels. Alcohol should be limited or eliminated.

Diabetes 93

Diabetes Exercise Obesity BMI 93

Cardiometabolic Health Congress

NOVEMBER 8, 2024

Healthcare professionals should consider pharmacotherapy options that address T2D, obesity, and liver disease: Statins : Statins are first-line therapies for managing dyslipidemia and reducing cardiovascular risk in patients with MASH. This dual action makes tirzepatide a promising option for treating MASH in patients with T2D and obesity.

Obesity 52

Obesity Exercise Risk Factors Cardiovascular Disease 52